Back to Condition
GNE myopathy
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

GNE myopathy

GNE myopathy is a progressive genetic muscle disorder that causes skeletal muscle weakness, typically starting with foot drop in late adolescence or early adulthood while sparing the quadriceps.

Overview

GNE myopathy is a condition that primarily affects skeletal muscles, which are the muscles the body uses for movement. This disorder causes muscle weakness that typically appears in late adolescence or early adulthood and worsens over time.

Symptoms

The symptoms of GNE myopathy progress gradually and are characterized by:

  • Difficulty lifting the front part of the foot (foot drop), which is often the first sign of the condition. This is caused by weakness in the tibialis anterior muscle of the lower leg.
  • Altered gait, making it difficult to run and climb stairs.
  • Progressive weakness in the muscles of the upper legs, hips, shoulders, and hands.
  • Sparing of the quadriceps (the large muscles at the front of the thigh), which are usually unaffected.
  • No involvement of the eye or heart muscles, and no associated neurological problems.
  • Increasing difficulty walking, with most affected individuals requiring wheelchair assistance within 20 years of symptom onset.

Frequency

Worldwide, fewer than 9 in 1,000,000 people are estimated to have GNE myopathy, though the actual number may be higher due to undiagnosed cases. The condition is more frequent among Japanese, Iranian Jewish, and Indian subcontinent populations.

Causes & Genetics

GNE myopathy is caused by variants (mutations) in the GNE gene. This gene provides instructions for making an enzyme involved in the chemical pathway that produces sialic acid, a simple sugar that attaches to the ends of complex molecules on cell surfaces.

Sialic acid influences several cellular functions, including:

  • Cell movement (migration).
  • Cell-to-cell attachment (adhesion).
  • Signaling between cells.
  • Inflammation.

Variants in the GNE gene reduce the activity of the enzyme, decreasing sialic acid production. This shortage leaves less sialic acid available to modify cell surface molecules. Researchers are still investigating why this shortage of sialic acid specifically leads to progressive muscle weakness in skeletal muscles while other tissues remain unaffected.

Associated Gene

  • GNE

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell must have a variant to cause the disorder. Parents of an affected individual each carry one copy of the altered gene but typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Distal myopathy with or without rimmed vacuoles
  • Distal myopathy with rimmed vacuoles (DMRV)
  • Distal myopathy, Nonaka type
  • Hereditary inclusion body myopathy type 2 (HIBM2)
  • IBM2
  • Inclusion body myopathy type 2
  • Inclusion body myopathy, hereditary, autosomal recessive
  • Inclusion body myopathy, quadriceps-sparing
  • Nonaka distal myopathy
  • Nonaka myopathy
  • QSM
  • Quadriceps-sparing myopathy

Frequently Asked Questions

The exact reason is not fully understood, but studies suggest that the distribution of sialic acid–dependent proteins varies among muscle types. Quadriceps and ocular muscles appear less dependent on the sialic acid pathway affected by GNE mutations, making them relatively resistant.
Early use of an ankle‑foot orthosis (AFO) can prevent foot drop and improve gait. Regular physiotherapy focusing on strengthening the tibialis anterior and calf muscles, combined with gait training, helps maintain mobility and reduces the risk of falls.
Yes, sequencing of the GNE gene can identify pathogenic variants. Individuals with a family history of the disease, or those who are part of high‑risk populations (Japanese, Iranian Jewish, Indian subcontinent), may benefit from predictive testing.
Research is underway into sialic acid supplementation, small‑molecule activators of the GNE enzyme, and gene‑replacement therapies. Patients can consult neuromuscular centers or the GNE Myopathy Foundation to learn about ongoing trials and eligibility criteria.===
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA